文献速递慢性肾脏病

较高剂量加巴喷丁类与老年慢性肾脏病患者不良事件风险:一项基于人群的队列研究

Higher-Dose Gabapentinoids and the Risk of Adverse Events in Older Adults With CKD: A Population-Based Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2021-12-31

该基于人群的队列研究纳入2008至2020年加拿大安大略省74,084例新处方加巴喷丁类的老年慢性肾脏病患者,比较较高剂量与较低剂量起始者30天内脑病、跌倒、骨折或呼吸抑制的复合结局风险。加权后较高剂量组风险高于较低剂量组(加权风险比1.27,95%CI 1.13-1.42)。

要点

  • 老年慢性肾脏病患者起始较高剂量加巴喷丁类与30天内脑病、跌倒、骨折或呼吸抑制复合结局风险轻度升高相关。
  • 加权后较高剂量组事件数为585/30,660(1.9%),较低剂量组为462/30,707(1.5%)。
  • 按估算肾小球滤过率类别和加巴喷丁类类型进行的预设亚组分析中,乘性和加性交互作用均未达统计学显著。

核心结论

  • 在这项基于人群的研究中,起始较高剂量加巴喷丁类与较低剂量相比,与30天内因脑病、跌倒或骨折就诊或因呼吸抑制住院的风险轻度升高相关。
  • 作者指出,若这些风险得到验证,应将较高剂量加巴喷丁类的风险与获益进行权衡。

研究设计与样本

  • 基于人群的队列研究,纳入2008至2020年加拿大安大略省74,084例新处方加巴喷丁类的老年慢性肾脏病患者(64%为女性;中位年龄79岁,四分位间距73-85岁)。
  • 慢性肾脏病在本研究中定义为估算肾小球滤过率<60 mL/min/1.73 m2,并排除接受透析者。
  • 采用倾向性评分分析中的逆概率治疗加权使比较组在基线健康指标上平衡,生成参考组伪样本使其测得的协变量分布与暴露组相似;加权后研究人群规模为61,367。
  • 加权风险比采用改良泊松回归估计,加权风险差采用二项回归估计。
  • 预设亚组分析按估算肾小球滤过率类别和加巴喷丁类类型进行。

主要发现

  • 在74,084例慢性肾脏病并新处方加巴喷丁或普瑞巴林的患者中,41%分别以>300 mg/d或>75 mg/d起始。
  • 加权人群中,较高剂量组与较低剂量组的事件数分别为585/30,660(1.9%)与462/30,707(1.5%)。
  • 加权风险比为1.27(95%CI 1.13-1.42),加权风险差为0.40%(95%CI 0.21%-0.60%)。
  • 亚组分析中,乘性和加性交互作用均未达统计学显著。

关键数值与推荐

  • 较高剂量加巴喷丁类定义为加巴喷丁>300 mg/d或普瑞巴林>75 mg/d;较低剂量定义为加巴喷丁≤300 mg/d或普瑞巴林≤75 mg/d。
  • 主要复合结局为30天内因脑病、跌倒或骨折就诊或因呼吸抑制住院的风险。
  • 加权风险比1.27(95%CI 1.13-1.42),加权风险差0.40%(95%CI 0.21%-0.60%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Gabapentinoids are opioid substitutes whose elimination by the kidneys is reduced as kidney function declines. To inform their safe prescribing in older adults with chronic kidney disease (CKD), we examined the 30-day risk of serious adverse events according to the prescribed starting dose. STUDY DESIGN: Population-based cohort study. SETTING & PARTICIPANTS: 74,084 older adults (64% women; median age, 79 [interquartile range, 73-85] years) with CKD (defined for this study as an estimated glomerular filtration rate <60 mL/min/1.73 m2 and excluding those receiving dialysis) and a newly prescribed gabapentinoid between 2008 and 2020 in Ontario, Canada. EXPOSURE: Higher-dose gabapentinoids (gabapentin >300 mg/d or pregabalin >75 mg/d) versus lower-dose gabapentinoids (gabapentin ≤300 mg/d or pregabalin ≤75 mg/d). OUTCOMES: The primary composite outcome was the 30-day risk of a hospital visit with encephalopathy, a fall, or a fracture or a hospitalization with respiratory depression. ANALYTICAL APPROACH: Comparison groups were balanced on indicators of baseline health using inverse probability of treatment weighting using propensity score analysis that generated a pseudosample for the reference group with a distribution of measured covariates similar to the exposed group. Weighted risk ratios were estimated using modified Poisson regression, and weighted risk differences were estimated using binomial regression. Prespecified subgroup analyses were conducted by estimated glomerular filtration rate category and type of gabapentinoid. RESULTS: Among 74,084 patients identified with CKD and a new prescription for gabapentin or pregabalin, 41% started at >300 or >75 mg/d, respectively. From this set of patients, a weighted study population with a size of 61,367 was generated. Patients who started at a higher dose had a higher 30-day risk of the primary outcome than patients who started at lower dose. Within the weighted population, the numbers of events for higher versus lower dose were 585 of 30,660 (1.9%) versus 462 of 30,707 (1.5%), respectively. The weighted risk ratio was 1.27 (95% CI, 1.13-1.42), and the weighted risk difference was 0.40% (95% CI, 0.21%-0.60%). In subgroup analyses, neither multiplicative nor additive interactions were statistically significant. LIMITATIONS: Residual confounding. CONCLUSIONS: In this population-based study, starting a gabapentinoid at a higher versus a lower dose was associated with a slightly higher risk of a hospital visit with encephalopathy, a fall, or a fracture or hospitalization with respiratory depression. If verified, these risks should be balanced against the benefits of using a higher-dose gabapentinoid.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Muanda FT, Weir MA, Ahmadi F, et al. Higher-Dose Gabapentinoids and the Risk of Adverse Events in Older Adults With CKD: A Population-Based Cohort Study. Am J Kidney Dis. 2021. PMID: 34979160. doi:10.1053/j.ajkd.2021.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。